Genetic conservation of SARS-CoV-2 RNA replication complex in globally circulating isolates and recently emerged variants from humans and minks suggests minimal pre-existing resistance to remdesivir

[1]  N. Krogan,et al.  Host-directed therapies against early-lineage SARS-CoV-2 retain efficacy against B.1.1.7 variant , 2021, bioRxiv.

[2]  Sergei L. Kosakovsky Pond,et al.  Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa , 2020, medRxiv.

[3]  M. Koopmans,et al.  Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans , 2020, Science.

[4]  D. Tegunov,et al.  Mechanism of SARS-CoV-2 polymerase inhibition by remdesivir , 2020, bioRxiv.

[5]  Vineet D. Menachery,et al.  A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19 , 2020, Nature Communications.

[6]  R. Jordan,et al.  Remdesivir targets a structurally analogous region of the Ebola virus and SARS-CoV-2 polymerases , 2020, Proceedings of the National Academy of Sciences.

[7]  Joy Y. Feng,et al.  Template-dependent inhibition of coronavirus RNA-dependent RNA polymerase by remdesivir reveals a second mechanism of action , 2020, The Journal of Biological Chemistry.

[8]  O. Tsang,et al.  Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. , 2020, JAMA.

[9]  B. Chait,et al.  Structural Basis for Helicase-Polymerase Coupling in the SARS-CoV-2 Replication-Transcription Complex , 2020, Cell.

[10]  B. Chait,et al.  Structural basis for helicase-polymerase coupling in the SARS-CoV-2 replication-transcription complex , 2020, bioRxiv.

[11]  R. Baric,et al.  Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice , 2020, Cell Reports.

[12]  R. Bruno,et al.  Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 , 2020, The New England journal of medicine.

[13]  L. Dodd,et al.  Remdesivir for the Treatment of Covid-19 — Final Report , 2020, The New England journal of medicine.

[14]  R. Berisio,et al.  A Structural View of SARS-CoV-2 RNA Replication Machinery: RNA Synthesis, Proofreading and Final Capping , 2020, Cells.

[15]  S. Anzick,et al.  Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2 , 2020, Nature.

[16]  Joy Y. Feng,et al.  Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency , 2020, The Journal of Biological Chemistry.

[17]  H. Feldmann,et al.  Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection , 2020, Proceedings of the National Academy of Sciences.

[18]  E. Holmes,et al.  Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding , 2020, The Lancet.

[19]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[20]  R. Baric,et al.  Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV , 2020, Nature Communications.

[21]  A. Ward,et al.  Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors , 2019, Nature Communications.

[22]  Xiaotao Lu,et al.  Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease , 2018, mBio.

[23]  Clemens Vonrhein,et al.  Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA , 2017, Proceedings of the National Academy of Sciences.

[24]  Lisa E. Gralinski,et al.  Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses , 2017, Science Translational Medicine.

[25]  A. Arvey,et al.  GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses , 2017, Scientific Reports.

[26]  Stefan Elbe,et al.  Data, disease and diplomacy: GISAID's innovative contribution to global health , 2017, Global challenges.

[27]  William A. Lee,et al.  Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys , 2016, Nature.

[28]  K. Katoh,et al.  MAFFT Multiple Sequence Alignment Software Version 7: Improvements in Performance and Usability , 2013, Molecular biology and evolution.